

# Pipeline Therapeutics Enters into Global License and Development Agreement with Janssen

Client News

April 17, 2023

Gunderson Dettmer represented client Pipeline Therapeutics, a clinical-stage biopharmaceutical company, to enter into a global license and development agreement with Janssen Pharmaceutica NV (Janssen) for the investigational compound, PIPE-307 to treat nervous system disorders.

Under the terms of the agreement, Pipeline will grant Janssen a worldwide, exclusive license to research, develop and commercialize PIPE-307 in all indications. Pipeline will have the right to continue to advance PIPE-307 for the treatment of relapsing-remitting multiple sclerosis (RRMS).

Pipeline will receive \$50 million in an upfront payment from Janssen and separately up to \$25 million in an equity investment from Johnson & Johnson Innovation. Pipeline is also eligible to receive approximately \$1 billion in success-based payments including clinical, regulatory and commercial milestones, as well as tiered double-digit royalty payments, which increase if the co-development option for PIPE-307 is exercised by Pipeline.

In the [announcement of the agreement](#), Pipeline's president and CEO Carmine Stengone said, "We are excited to announce this agreement, which is aligned with our vision to maximize the reach of PIPE-307 through clinical evaluation in RRMS and other neurological disorders. In addition, we are pleased that we will strengthen our financial position with the upfront payment from this agreement and equity

investments from existing and new investors, enabling us to extend our runway and to continue advancing our portfolio in small molecule neuroregeneration.”

The Gunderson Dettmer deal team was led by Brendan McCarthy and included Jeff Thacker, Gregory Kinzelman and Alex Lee.

## Companies

Pipeline Therapeutics

Janssen Pharmaceutica

## Related People

Brendan C. McCarthy

PARTNER

P +1 858 436 8013

Jeffrey C. Thacker

PARTNER

P +1 858 436 8064

Gregory L. Kinzelman

PARTNER

P +1 646 797 5528

Alex Lee

ASSOCIATE

P +1 858 436 8057

## Related Services

Private & Public Companies

## Featured Insights

PUBLIC VENTURES

Trump Executive Order Targets Proxy Advisors Over DEI and ESG Influence

EVENTS

-----  
Webinar: Paradigm Shift? Mandatory Securities Arbitration and the Impact of the SEC's Recent Policy Statement for Companies and Investors

FIRM NEWS

Amidst Strong Year, Gunderson Dettmer Elects Nine New Partners

EVENTS

Webinar: AI in the Workplace: Legal Challenges and Best Practices

FIRM NEWS

2025 CVCA Annual General Meeting & Private/Venture Capital Summit in Beijing

CLIENT NEWS

Gunderson Dettmer Represented Hims & Hers in Acquisition of Livewell

CLIENT NEWS

Replicate Bioscience Announces Collaborative Agreement with Instituto Butantan

CLIENT NEWS

Gunderson Client Neptune to Be Acquired by OpenAI

CLIENT NEWS

Hims & Hers Announces Definitive Agreement to Acquire YourBio Health

CLIENT NEWS

LotusFlare Announces Equity Investment from Ericsson

PUBLIC VENTURES

SEC Chair Charts Disclosure Overhaul to Revive IPOs: Materiality and Scale Over 'Regulatory Creep'

CLIENT NEWS

Vambe Raises \$14M Series A Led by Monashees